REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback